Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 316

1.

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daëron M.

Blood. 2009 Apr 16;113(16):3716-25. doi: 10.1182/blood-2008-09-179754.

2.

Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.

Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.

J Immunol Methods. 2011 Feb 28;365(1-2):132-41. doi: 10.1016/j.jim.2010.12.014.

PMID:
21185301
3.

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M.

Clin Cancer Res. 2006 May 1;12(9):2879-87.

4.

The influence of the hinge region length in binding of human IgG to human Fcgamma receptors.

Redpath S, Michaelsen TE, Sandlie I, Clark MR.

Hum Immunol. 1998 Nov;59(11):720-7.

PMID:
9796740
5.

Expression of human FcgammaRIIIa as a GPI-linked molecule on CHO cells to enable measurement of human IgG binding.

Armour KL, Smith CS, Clark MR.

J Immunol Methods. 2010 Mar 31;354(1-2):20-33. doi: 10.1016/j.jim.2010.01.011.

PMID:
20138184
6.

IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.

Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.

J Immunol Methods. 2005 Nov 30;306(1-2):151-60.

PMID:
16219319
7.

Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.

Kumpel BM, Beliard R, Brossard Y, Edelman L, de Haas M, Jackson DJ, Kooyman P, Ligthart PC, Monchâtre E, Overbeeke MA, Puillandre P, de Romeuf C, Wilkes AM.

Transfus Clin Biol. 2002 Jan;9(1):45-53.

PMID:
11889899
8.

Affinity of the interaction between Fc gamma receptor type III (Fc gammaRIII) and monomeric human IgG subclasses. Role of Fc gammaRIII glycosylation.

Galon J, Robertson MW, Galinha A, Mazières N, Spagnoli R, Fridman WH, Sautès C.

Eur J Immunol. 1997 Aug;27(8):1928-32.

PMID:
9295028
9.

Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies.

Armour KL, van de Winkel JG, Williamson LM, Clark MR.

Mol Immunol. 2003 Dec;40(9):585-93.

PMID:
14597161
10.
11.
12.

No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis.

Tse WY, Abadeh S, McTiernan A, Jefferis R, Savage CO, Adu D.

Clin Exp Immunol. 1999 Jul;117(1):198-205.

13.

Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, Koenig S.

Cancer Res. 2007 Sep 15;67(18):8882-90. Erratum in: Cancer Res. 2008 Sep 15;68(18):7692. Vijh, Sujata [added].

14.

Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index.

McDonagh CF, Kim KM, Turcott E, Brown LL, Westendorf L, Feist T, Sussman D, Stone I, Anderson M, Miyamoto J, Lyon R, Alley SC, Gerber HP, Carter PJ.

Mol Cancer Ther. 2008 Sep;7(9):2913-23. doi: 10.1158/1535-7163.MCT-08-0295.

15.

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity.

Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG.

J Biol Chem. 2002 Jul 26;277(30):26733-40.

PMID:
11986321
16.

Differential recruitment of activating and inhibitory Fc gamma RII during phagocytosis.

Syam S, Mero P, Pham T, McIntosh CA, Bruhns P, Booth JW.

J Immunol. 2010 Mar 15;184(6):2966-73. doi: 10.4049/jimmunol.0900016.

17.

Hyperacute rejection by anti-Gal IgG1, IgG2a, and IgG2b is dependent on complement and Fc-gamma receptors.

Ding JW, Zhou T, Zeng H, Ma L, Verbeek JS, Yin D, Shen J, Chong AS.

J Immunol. 2008 Jan 1;180(1):261-8.

18.

Canine mast cell activation via human IgG1 and IgG4.

Sato Y, Teshima R, Nakamura R, Takagi K, Sasaki N, Sawada J, Kitani S.

Int Arch Allergy Immunol. 2004 Oct;135(2):154-60.

PMID:
15345915
19.

Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa.

Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, Tsumoto K, Kumagai I, Shitara K.

J Mol Biol. 2004 Mar 5;336(5):1239-49.

PMID:
15037082
20.

Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity.

Nagashima H, Tezuka T, Tsuchida W, Maeda H, Kohroki J, Masuho Y.

Mol Immunol. 2008 May;45(10):2752-63. doi: 10.1016/j.molimm.2008.02.003.

PMID:
18353438
Items per page

Supplemental Content

Support Center